The HLA/lmmunogenetics Laboratory, directed by Dr. Elizabeth trachtenberg at Children's Hospital Oakland Research Institute (CHORI), will continue in their role as the KIR Genotyping Core Laboratory to explore in further detail the hetrogeneity of KIR at the allelic level, and the role of KIR-HLA associations in unrelated hematopoietic stem cell transplantations (HCT) for acute myelogenous leukemia (AML). Data from this core was key to the Project's seminal analyses of KIR and HLA ligand genetics in HCT showing improved relapse-free survival with B haplotype donors in HCT for AML(detailed in Projects 1 and 3). The Laboratory has a proven track record with high-throughput, high complexity genetic analyses and assay development, and have the necessary quality assurance expertise and equipment necessary to fulfill this role. The KIR Genotyping Core Laboratory will analyze samples requiring locus-specific characterization using the well proven MALDI-TOF assay, or clinically validated sequence-specific priming (SSP) kits. The Laboratory will next shift into KIR allelic analysis utilizing a novel, next-generation clonal sequencing of all KIR genes. Formal validation of our novel protocol to characterize all ofthe KIR loci on multiple samples simultaneously, utilizing the Roche 454 Genome Sequencer FLX Titanium platform, will be finished in the first year of this POI renewal, and a computer program to analyze the data and report all KIR alleles will be developed in collaboration with Dr. Damian Goodridge (Conexio Genomics).
The specific aims of this Core Laboratory for the five year time period are: 1) continue refinement and validation of our KIR sequencing assay to clonally sequence all KIR genes on samples using the Roche GS FLX platform;2a) perform KIR allelic sequencing of samples in support of a retrospective study of outcome analysis of HCT for AML (Project 1), and 2b) to perform locus-specific KIR analysis of samples for studies within the critical time frames required forthe prospective clinical studies (Projects 2 and 3);and 3) implement a quality assurance (QA) program, including 15% duplicate and blinded typings. No other lab is as prepared to provide the rapid KIR genotyping and QA measures necessary to adequately serve the typing needs of these projects.

Public Health Relevance

KIR genotyping results in superior relapse free survival using B/x donors in HCT for AML. This association with be refined to tease out genetic components that best predict clinical benefit. Development of nextgeneration sequencing methods to analyze KIR alleles will change practice by providing a comprehensive overview on the role of both inhibitory and stimulatory KIR alleles acting alone or in combination in HCT.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Presnell, S R; Al-Attar, A; Cichocki, F et al. (2015) Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. Genes Immun 16:89-98
Cichocki, Frank; Schlums, Heinrich; Li, Hongchuan et al. (2014) Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med 211:1079-91
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Bachanova, Veronika; Miller, Jeffrey S (2014) NK cells in therapy of cancer. Crit Rev Oncog 19:133-41
Foley, Bree; Felices, Martin; Cichocki, Frank et al. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 258:45-63
Miller, Jeffrey S; Rooney, Cliona M; Curtsinger, Julie et al. (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20:1252-7
Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97
Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26
Sarkar, Chandrima; Cooley, Sarah; Srivastava, Jaideep (2014) Robust Feature Selection Technique using Rank Aggregation. Appl Artif Intell 28:243-257
Bachanova, Veronika; Cooley, Sarah; Defor, Todd E et al. (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855-63

Showing the most recent 10 out of 44 publications